Biopreservation of living tissue engineered nerve grafts.

Autor: Shultz RB; Center for Neurotrauma, Neurodegeneration & Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.; Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.; Department of Chemistry and Chemical Biology, School of Arts and Sciences, Rutgers University, Piscataway, NJ, USA.; Axonova Medical, LLC, Philadelphia, PA, USA., Katiyar KS; Center for Neurotrauma, Neurodegeneration & Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.; Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.; Axonova Medical, LLC, Philadelphia, PA, USA., Laimo FA; Center for Neurotrauma, Neurodegeneration & Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.; Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA., Burrell JC; Center for Neurotrauma, Neurodegeneration & Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.; Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.; Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, USA., Browne KD; Center for Neurotrauma, Neurodegeneration & Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.; Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA., Ali ZS; Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.; Penn Nerve Center, University of Pennsylvania, Philadelphia, PA, USA., Cullen DK; Center for Neurotrauma, Neurodegeneration & Restoration, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.; Center for Brain Injury and Repair, Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA, USA.; Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, USA.; Axonova Medical, LLC, Philadelphia, PA, USA.
Jazyk: angličtina
Zdroj: Journal of tissue engineering [J Tissue Eng] 2021 Aug 11; Vol. 12, pp. 20417314211032488. Date of Electronic Publication: 2021 Aug 11 (Print Publication: 2021).
DOI: 10.1177/20417314211032488
Abstrakt: Tissue engineered nerve grafts (TENGs) built from living neurons and aligned axon tracts offer a revolutionary new approach as "living scaffolds" to bridge major peripheral nerve defects. Clinical application, however, necessitates sufficient shelf-life to allow for shipping from manufacturing facility to clinic as well as storage until use. Here, hypothermic storage in commercially available hibernation media is explored as a potential biopreservation strategy for TENGs. After up to 28 days of refrigeration at 4℃, TENGs maintain viability and structure in vitro . Following transplantation into 1 cm rat sciatic defects, biopreserved TENGs routinely survive and persist for at least 2 weeks and recapitulate pro-regenerative mechanisms of fresh TENGs, including the ability to recruit regenerating host tissue into the graft and extend neurites beyond the margins of the graft. The protocols and timelines established here serve as important foundational work for the manufacturing, storage, and translation of other neuron-based tissue engineered therapeutics.
Competing Interests: Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.K.C. is a co-founder and K.S.K. and R.B.S. are employees of Axonova Medical, LLC, which is a University of Pennsylvania spin-out company focused on translation of advanced regenerative therapies to treat nervous system disorders. Multiple patents related to the composition, methods, and use of tissue engineered nerve grafts, including U.S. Patent 9,895,399 (D.K.C.), US Patent 10,525,085 (D.K.C.), U.S. Patent App. 16/753,634; (D.K.C), and U.S. Provisional Patent App. 62/937,489 (D.K.C & J.C.B.). No other author has declared a potential conflict of interest.
(© The Author(s) 2021.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje